Cart
sales@molnova.com
Nurulimab
CAS No. 2168561-20-2
Nurulimab( —— )
Catalog No. M36820 CAS No. 2168561-20-2
Nurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 299 | Get Quote |
|
| 5MG | 490 | Get Quote |
|
| 10MG | 787 | Get Quote |
|
| 25MG | 1132 | Get Quote |
|
| 50MG | 1518 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNurulimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionNurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.
-
DescriptionNurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) humanized monoclonal antibody. Nurulimab can be can be used in research of melanoma.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2168561-20-2
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 34, No. 1, 2020.
molnova catalog
related products
-
Methyl Blue
Methyl blue is a triaminotriphenylmethane dye. It is used as an antiseptic dye in the polychrome staining method and has applications in histological and microbiological staining solutions.
-
GSK-25
GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC50 of 398 nM, p70S6K IC50 of 1000nM), and a dramatically improved P450 profile (>2.2 uM at all isozymes tested).
-
TrxR1-IN-B19
TrxR1-IN-B19, a TrxR1 inhibitor, selectively kills gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation.
